Saniona is a research and development company focused on drugs for diseases of the central nervous system and eating disorders. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION).
How many staff members are on the team currently & do you find it difficult to find quality local and international staff?
An essential part of Saniona from the very beginning was the unique ion channel research team which I have been working with for more than 20 years. We are now 25 people in the core team and additional 20 international consultants working in Saniona development. Moreover, a team of around 20 chemists work for us at a contract house in India. So far we have had no problems in attracting highly competent people.
Do any of the staff and or management team hold any shares within the company?
Most employees are shareholders in the company and together with management/board holds about half of the shares in the company. Management (CEO+CFO) together holds about 20% of the company shares.
During your time at the company, what's been your greatest achievement thus far?
Just a couple of months ago our product tesofensine for treatment of obesity completed a final Phase 3 registration study and could within a year or so become the first marketed product for Saniona.
What is your medium to long-term goal & has it been consistent for some time?
Saniona’s primary focus is treatment of rare eating disorders where we currently conduct studies in Prader Willi Syndrome and Hypothalamic obesity. Our long-term goal has for quite some time been to bring our product Tesomet to the market ourselves in these rare diseases.
What sets your company apart from others within your industry?
Most companies in “Swedish Biotech” are one product companies with more or less virtual organizations. Often the risk is high since it has not been proven that the product works in the clinic.
Saniona has a broad pipeline of programs, some for own development and commercialization, others are partnered. We have products that work! With strong efficacy of tesofensine and Tesomet from phase 2 or Phase 3 studies. We have a balanced risk profile due to our many partnerships based on our unique ion channel platform – that’s our X-factor.
Could you please share with us your favourite memory and or event since you joined the company?
A few times I could not help bursting out in extreme delight when we landed positive clinical data confirming that our products work, but probably the most fantastic memories come from when we signed and celebrated large partnering deals with Pharma companies. This is to me the ultimate validation of our team, programs and technology.